

Date: 6 April 2022

**Re: Freedom of Information Request**

**Ref: 78-2022**

Thank you for your email dated the 10/3/2022, requesting information in relation to squamous cell carcinoma and urothelial cell

The information that you require is as follows:

**1. How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:**

- Carboplatin (monotherapy or in combination with 5-FU) **18**
- Cisplatin (monotherapy or in combination with 5-FU) **12**
- Cetuximab with/without chemotherapy **1**
- Cetuximab with radiotherapy **2**
- Pembrolizumab monotherapy **29**
- Pembrolizumab with chemotherapy **0**
- Nivolumab **10**
- Docetaxel (monotherapy or in combination with 5-FU) **3**
- Fluorouracil (5FU) **0**
- Radiotherapy only **0**
- Other

Carboplatin + Paclitaxel (3 weekly)	<b>1</b>
Cemiplimab	<b>1</b>
Cisplatin + Radiotherapy	<b>34</b>
Denosumab	<b>2</b>
DURVALUMAB	<b>2</b>
Paclitaxel 7 day	<b>3</b>
TG4050 (Transgene Trial)	<b>2</b>

**2. For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:**

- Total number of head and neck cancer patients **104**
- Number of locally advanced head and neck cancer patients **75**

- Number of recurrent and/or metastatic head and neck cancer patients **8**

**3. How many Urothelial cancer patients have been treated in the past 3 months with the following agents:**

- Atezolizumab **0**
- Carboplatin with Gemcitabine **0**
- Carboplatin single or in any other combination **0**
- Cisplatin with Gemcitabine **0**
- Cisplatin single or in any other combination **0**
- Nivolumab **0**
- Pembrolizumab **0**
- Any other regimen including Paclitaxel **0**
- Any other chemotherapy regimen **0**
- Other active systemic anti-cancer therapy [please state] **0**
- Palliative care only **0**

**4. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?**

**Open to Recruitment**

Project Acronym	Project Full title	Project phase	Project site date open to recruitment	Recruited	Project site actual recruitment end date
<b>ANNAR (EDDA)</b>	Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations	Not Applicable	17/12/2020	<b>8</b>	

**Closed to Recruitment – In follow-up**

Project Acronym	Project Full title	Project phase	Project site date open to recruitment	Recruited	Project site actual recruitment end date
<b>BAYER 17403</b>	A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	Phase II/III	23/08/2018	<b>10</b>	05/09/2019
<b>EV-301</b>	An Open-Label, Randomised Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	Phase III	22/07/2019	<b>5</b>	23/01/2020
<b>JANSSEN BLADDER</b>	A Phase II, 2-Arm MultiCenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	Phase II	22/10/2015	<b>1</b>	01/05/2017
<b>MK3475</b>	A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	Phase II	17/08/2015	<b>4</b>	13/06/2016
<b>RANGE</b>	RANGE - Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable	Phase III	06/10/2015	<b>12</b>	21/03/2017

	or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy				
<b>POUT</b>	POUT - A Phase III randomised trial of PeriOperative chemotherapy versus sUrveillance in upper Tract urothelial cancer	Phase III	23/07/2012	<b>6</b>	10/11/2017

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

The Information Governance Team  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)